By InvitationNot Applicable

Effect of Serum Vitamin D on MARPE Treatment Response

Turkey (Türkiye)20 participantsStarted 2025-02-20

Plain-language summary

A total of 30 patients are planned to be included in the study during the first half of 2025, who will apply to the clinic. In our clinical routine, approximately 30% of RME patients are treated using the MARPE method. The patients will be randomly assigned to two different groups. The first group will be referred to the Pediatric Endocrinology outpatient clinic at NEU Faculty of Medicine for vitamin D level measurements at the beginning of the treatment. The second group will proceed with treatment as usual, without vitamin D measurement. At the end of the treatment, vitamin D levels of all patients in both groups will be measured.

Who can participate

Age range16 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients diagnosed with Class I malocclusion * Presence of maxillary transverse deficiency * Adolescents aged between 15 and 18 years * No systemic diseases, cleft lip/palate, or speech disorders * No history of prior orthodontic treatment * Willingness to undergo serum vitamin D testing * Voluntary participation in the study with signed informed consent * Good oral hygiene status Exclusion Criteria: * Patients with systemic diseases * Patients who smoke * Patients with poor oral hygiene * Patients with cooperation or compliance issues * Patients with intellectual disabilities * Patients with unmonitored or insufficient pre-treatment vitamin D levels, including: * Those who had insufficient vitamin D levels before treatment, were started on supplementation by the endocrinology department, but still had insufficient levels at the T2 measurement * Those who were not tested before treatment but were found to have sufficient vitamin D levels only at T2

What they're measuring

Change in Intermolar and Intercanine Widths After MARPE Treatment

Timeframe: At baseline (T1) and after expansion phase (T2), approximately 6 weeks apart

Trial details

NCT IDNCT06943443

SponsorKonya Necmettin Erbakan Üniversitesi

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-08-30